JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Benitec Biopharma (BNTC – Research Report) today and set a price target of $6.00. The company’s shares closed yesterday at $3.15.
According to TipRanks, Tuerkcan is a 2-star analyst with an average return of 0.9% and a 27.18% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Exelixis, Mirati Therapeutics, and Taysha Gene Therapies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Benitec Biopharma with a $6.00 average price target.
See the top stocks recommended by analysts >>
BNTC market cap is currently $7.77M and has a P/E ratio of -0.18.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Benitec Biopharma (BNTC) Company Description:
Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in North Sydney, Australia.
Read More on BNTC:
- Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
- Benitec Biopharma reports 2023 EPS ($14.12) vs. ($37.88) last year
- Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
- Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
